DiaMedica Therapeutics Current Ratio vs. Market Capitalization

DMAC Stock  USD 5.66  0.45  8.64%   
Based on DiaMedica Therapeutics' profitability indicators, DiaMedica Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess DiaMedica Therapeutics' ability to earn profits and add value for shareholders.
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
19.26597272
Current Value
20.23
Quarterly Volatility
9.25912841
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of November 29, 2024, Price To Sales Ratio is expected to decline to 49.24. In addition to that, Days Sales Outstanding is expected to decline to 358.33. At present, DiaMedica Therapeutics' Income Tax Expense is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 47.1 K, whereas Accumulated Other Comprehensive Income is forecasted to decline to 5,700.
For DiaMedica Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DiaMedica Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DiaMedica Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DiaMedica Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DiaMedica Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Return On Assets
(0.24)
Return On Equity
(0.35)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

DiaMedica Therapeutics Market Capitalization vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining DiaMedica Therapeutics's current stock value. Our valuation model uses many indicators to compare DiaMedica Therapeutics value to that of its competitors to determine the firm's financial worth.
DiaMedica Therapeutics is rated # 2 in current ratio category among its peers. It is rated # 5 in market capitalization category among its peers creating about  8,736,577  of Market Capitalization per Current Ratio. At present, DiaMedica Therapeutics' Current Ratio is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DiaMedica Therapeutics' earnings, one of the primary drivers of an investment's value.

DiaMedica Market Capitalization vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

DiaMedica Therapeutics

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
25.50 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

DiaMedica Therapeutics

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
222.78 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

DiaMedica Market Capitalization vs Competition

DiaMedica Therapeutics is rated # 5 in market capitalization category among its peers. Market capitalization of Health Care industry is currently estimated at about 8.28 Billion. DiaMedica Therapeutics holds roughly 222.78 Million in market capitalization claiming about 2.69% of equities under Health Care industry.
Capitalization  Valuation  Workforce  Total debt  Revenue

DiaMedica Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in DiaMedica Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, DiaMedica Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of DiaMedica Therapeutics' change in net profit over the period of time. It can combine multiple indicators of DiaMedica Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeK5.7 K
Operating Income-21.3 M-20.2 M
Income Before Tax-19.3 M-18.4 M
Total Other Income Expense Net1.9 MM
Net Loss-19.4 M-18.4 M
Income Tax Expense43 K45.2 K
Net Loss-18 M-17.1 M
Net Loss-12.2 M-11.6 M
Non Operating Income Net Other499.1 K461.3 K
Net Interest Income-1.1 K-1.2 K
Interest Income44.9 K47.1 K
Change To Netincome1.8 M1.9 M
Net Loss(0.60)(0.62)
Income Quality 0.97  1.05 
Net Income Per E B T 1.00  1.12 

DiaMedica Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on DiaMedica Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DiaMedica Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DiaMedica Therapeutics' important profitability drivers and their relationship over time.

Use DiaMedica Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.

DiaMedica Therapeutics Pair Trading

DiaMedica Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your DiaMedica Therapeutics position

In addition to having DiaMedica Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Robots And Drones Thematic Idea Now

Robots And Drones
Robots And Drones Theme
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
View All  Next Launch
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out Investing Opportunities.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
To fully project DiaMedica Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DiaMedica Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DiaMedica Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential DiaMedica Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although DiaMedica Therapeutics investors may work on each financial statement separately, they are all related. The changes in DiaMedica Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DiaMedica Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.